EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis

Michelle B R G Ley iD, Marc C Philippon, Ramy S Labib, Miguel Fuentes-Chandia iD, Chao Liu iD, Thomas M Best iD, Rodrigo A Somoza, Dimitrios Kouroupis iD

International Journal of Molecular Sciences · 05.11.2026 · 27 (21) · 9922

DOI: 10.3390/ijms27219922 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2026. Verfasst von Michelle B R G Ley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Extracellular Vesicles, Osteoarthritis, Immunomodulation. Die Arbeit nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Diabetes Research Institute Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a heterogeneous disorder affecting multiple joint tissues, in which structural degeneration may be accompanied by varying degrees of synovial inflammation and immune–stromal dysregulation. Mesenchymal stem/stromal cells (MSCs) have demonstrated immunomodulatory and tissue-protective properties, increasingly linked to paracrine signaling. Comparative studies suggest that extracellular vesicles (EVs) make an important, but not exclusive, contribution to MSC paracrine activity, with soluble secretome components providing potentially complementary effects. Drawing on literature identified primarily through PubMed and Scopus and clinical trial records from ClinicalTrials.gov (updated through September 2026), this narrative review examines the immunomodulatory role of MSC-derived EVs (MSC-EVs) in OA, with emphasis on their interactions with the joint immune microenvironment and their contribution to tissue protection. Across experimental OA models, MSC-EVs have been reported to reduce synovitis, cartilage degeneration, subchondral bone alterations, and pain-related outcomes, although responses vary with MSC source, EV composition, engineering strategies, disease context, and treatment regimen. Mechanistically, the most consistent evidence supports modulation of macrophage-associated inflammatory responses, whereas effects on adaptive immune populations remain less established and are largely derived from non-OA models. Clinical evidence remains limited and currently provides mainly preliminary information on feasibility and short-term tolerability, with insufficient evidence to establish therapeutic efficacy. Overall, MSC-EVs represent a potential cell-free immunomodulatory approach for OA, but standardized manufacturing, product characterization, dosing, and rigorously controlled clinical trials are required to define their therapeutic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsExtracellular VesiclesOsteoarthritisImmunomodulationHumansAnimals

Stichwörter der Autor:innen

cell-free therapyclinical translationextracellular vesiclesimmune–stromal crosstalkimmunomodulationmesenchymal stem/stromal cellsosteoarthritissynovial macrophagessynovitis

Autor:innen und Institutionen

  • Department of Orthopedics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Diabetes Research Institute & Cell Transplant Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Center for the Multimodal Evaluation of Structural Tissues, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Asclepii Inc., Cleveland, OH 44106, USA.
  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA.

ORCID-Profile: Michelle B R G Ley, Miguel Fuentes-Chandia, Chao Liu, Thomas M Best, Dimitrios Kouroupis

Förderung

  • National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Diabetes Research Institute Foundation

Zitieren

APA

Ley, M. B. R. G., Philippon, M. C., Labib, R. S., Fuentes-Chandia, M., Liu, C., Best, T. M., Somoza, R. A., & Kouroupis, D. (2026). Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis. International Journal of Molecular Sciences, 27(21), 9922. https://doi.org/10.3390/ijms27219922

Vancouver

Ley MBRG, Philippon MC, Labib RS, Fuentes-Chandia M, Liu C, Best TM, et al. Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis. International Journal of Molecular Sciences. 2026;27(21):9922. doi:10.3390/ijms27219922

BibTeX
@article{Ley2026,
  author = {Ley, Michelle B R G and Philippon, Marc C and Labib, Ramy S and Fuentes-Chandia, Miguel and Liu, Chao and Best, Thomas M and Somoza, Rodrigo A and Kouroupis, Dimitrios},
  title = {Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9922},
  doi = {10.3390/ijms27219922}
}
Kostenlos starten →